Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kosuke Kosai is active.

Publication


Featured researches published by Kosuke Kosai.


Journal of Infection and Chemotherapy | 2014

Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: A review of the Japanese literature

Koichi Izumikawa; Kinichi Izumikawa; Takahiro Takazono; Kosuke Kosai; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Misuzu Tsukamoto; Katsunori Yanagihara; Kohei Hara; Shigeru Kohno

Mycoplasma pneumoniae (MP) is one of the most common causes of community-acquired pneumonia in children and young adults. Although MP sometimes causes self-limiting pneumonia, severe and fulminant cases with hypoxia occur, but their clinical features have rarely been reported. This study aimed to reveal the clinical manifestations, risk factors, and treatment of fulminant MP pneumonia (MPP). Using PubMed and abstracts from the proceedings of several domestic Japanese academic societies, we reviewed the Japanese and English literature for cases of fulminant or severe MPP reported in Japan. All clinical information such as sex, age, underlying diseases, clinical symptoms, clinical course, laboratory and radiological findings, and treatment was collected and analyzed. In total, 52 fulminant MPP cases were reported between September, 1979 and February, 2010. The dominant population of fulminant MPP was young adults without severe underlying diseases. Cough (97.3%), fever (100.0%), and dyspnea (83.3%) with diffuse abnormal findings in radiological examinations were noted. Antibiotics without anti-mycoplasmal activity were used in 32 cases (61.5%) as initial treatment prior to the onset of hypoxia. Anti-mycoplasmal drugs were appropriately used in 41 cases (78.8%) after onset of respiratory failure with steroids (23 cases, 45.1%) and effective. The majority of patients improved within 3-5 days after steroid administration. There were only 2 fatal cases. Although this small retrospective study did not reveal the apparent risk factors of fulminant MPP, initial inappropriate use of antibiotics may be a risk factor, and early administration of appropriate anti-mycoplasmal drugs with steroids as a cellular immune suppressor is required.


Mycopathologia | 2010

Skn7p is involved in oxidative stress response and virulence of Candida glabrata.

Tomomi Saijo; Taiga Miyazaki; Koichi Izumikawa; Tomo Mihara; Takahiro Takazono; Kosuke Kosai; Yoshifumi Imamura; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Shigeru Kohno

Candida glabrata is an opportunistic fungal pathogen that causes both superficial and deep-seated mycosis in humans. In Saccharomyces cerevisiae and several pathogenic fungi, Skn7p is known as a transcriptional factor involved in oxidative stress response (OSR) but functions of its ortholog have been little investigated in C. glabrata. In this study, we constructed a C. glabrataskn7 deletion strain by the ura-blaster technique and investigated mutant phenotypes related to OSR and virulence. The C. glabrataskn7 deletant showed increased susceptibility to hydrogen peroxide and tert-butyl hydroperoxide. Our transcriptional assay evaluated by quantitative real-time PCR revealed that, in response to the treatment with hydrogen peroxide, transcription of some putative Skn7p target genes including TRX2, TRR1, TSA1 and CTA1 were not fully induced in the skn7 deletant compared to the wild-type control, consistent with the susceptibility phenotype. Furthermore, the deletion of SKN7 resulted in attenuated virulence in a murine model of disseminated candidiasis. These results suggest that Skn7p may play a role in transcriptional regulation of its target genes required for OSR and virulence in C. glabrata.


Scandinavian Journal of Infectious Diseases | 2008

Elevated levels of high mobility group box chromosomal protein-1 (HMGB-1) in sera from patients with severe bacterial pneumonia coinfected with influenza virus.

Kosuke Kosai; Masafumi Seki; Katsunori Yanagihara; Shigeki Nakamura; Shintaro Kurihara; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Takayoshi Tashiro; Shigeru Kohno

Plasma levels of high mobility group box chromosomal protein-1 (HMGB-1), as well as of other inflammatory molecules such as interleukin-6 (IL-6), regulated on activation normal T-cell expressed and secreted (RANTES), and soluble intercellular adhesion molecule-1 (sICAM-1), were determined in patients with bacterial pneumonia coinfected with influenza virus. HMGB-1 levels were significantly elevated in these patients compared to patients undergoing mild bacterial pneumonia alone (p<0.01). Among cases of coinfection, we found a significant correlation between the concentration of HMGB-1 and white blood cell counts (p<0.05, r=0.612). Levels of IL-6 were also higher in these patients than in patients with bacterial pneumonia alone (p<0.05), despite similar levels of RANTES and sICAM-1 in the 2 groups. These data suggest that HMGB-1 is involved in the pathogenesis of severe bacterial pneumonia coinfected with influenza virus.


Letters in Applied Microbiology | 2011

Lactobacillus pentosus strain b240 suppresses pneumonia induced by Streptococcus pneumoniae in mice

Akitaka Tanaka; Masafumi Seki; Satoko Yamahira; Hiroki Noguchi; Kosuke Kosai; Masamichi Toba; Yoshitomo Morinaga; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Takayoshi Tashiro; Noriyuki Kohda; Shigeru Kohno

Aims:  Oral administration of probiotics has been known to improve inflammatory responses against infectious diseases. Here, we describe the inhibitory effect of oral intake of heat‐killed Lactobacillus pentosus strain b240 (b240) on pneumococcal pneumonia in a murine experimental model.


Medical Mycology | 2016

The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfected with nontuberculous mycobacteria

Kazuaki Takeda; Yoshifumi Imamura; Takahiro Takazono; Masataka Yoshida; Shotaro Ide; Katsuji Hirano; Masato Tashiro; Tomomi Saijo; Kosuke Kosai; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Misuzu Tsukamoto; Taiga Miyazaki; Takayoshi Tashiro; Shigeru Kohno; Katsunori Yanagihara; Koichi Izumikawa

Patients with chronic pulmonary aspergillosis (CPA) have a poor prognosis and CPA occurs in patients with various underlying diseases. Recently, the number of patients with CPA complicated by nontuberculous mycobacteria (NTM) has increased. Additionally, complications of both diseases have several problems like drug interactions. Since the impact of NTM on the outcome of CPA is not well understood, we investigated the risk factors for developing CPA and the clinical characteristics of CPA patients with or without NTM. We retrospectively investigated the medical records of NTM and CPA patients who were admitted to Nagasaki University Hospital between April 2008 and September 2013. Comorbid diseases, causative microorganisms, radiological findings, and outcomes were evaluated. During the study period, 82 and 41 patients were diagnosed as having NTM and CPA, respectively. Nine patients were coinfected with NTM and CPA, and cavitary type NTM and steroid usage were independent risk factors of development of CPA. Mortality rates in the coinfection group were significantly higher than those of the NTM without CPA group (P = .003, log-rank test). The rate of treatment initiation in the co-infection group (33.3%) was significantly lower than in the CPA without NTM group (84.4%) (P = .006). However, there were no significant differences in cumulative survival rate between both groups (P = .760, log-rank test). Cavity formation and steroid usage were the independent risk factors for NTM patients to develop CPA within long observation period, and development of CPA made outcomes poor. It is important to diagnose the development of CPA early and initiate treatment for CPA.


PLOS ONE | 2014

Efficacy of Combination Therapy with Oseltamivir Phosphate and Azithromycin for Influenza: A Multicenter, Open-Label, Randomized Study

Hiroshi Kakeya; Masafumi Seki; Koichi Izumikawa; Kosuke Kosai; Yoshitomo Morinaga; Shintaro Kurihara; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Misuzu Tsukamoto; Katsunori Yanagihara; Takayoshi Tashiro; Shigeru Kohno

Background Macrolides have antibiotic and immunomodulatory activities, which may have a favorable effect on the clinical outcome of patients with infections, including influenza. This study aimed to evaluate the effects of combination therapy with an anti-influenza agent, oseltamivir, and a single-dose formulation of azithromycin (AZM), which has been used for influenza-related secondary pneumonia, on influenza patients. The primary endpoint was a change in the expression levels of inflammatory cytokines. Secondary endpoints were the time required for resolution of influenza-related symptoms, incidence of complications, and adverse reactions. Methods Patients with seasonal influenza were enrolled in this multicenter, open-label, randomized study. Patients were stratified according to the presence of a high risk factor and were randomized to receive combination therapy with oseltamivir plus an extended-release formulation of AZM (combo-group) or oseltamivir monotherapy (mono-group). Results We enrolled 107 patients and randomized them into the mono-group (56 patients) or the combo-group (51 patients). All patients were diagnosed with influenza A infection, and none of the patients had comorbid pneumonia. Statistically significant differences were not observed in the expression levels of inflammatory cytokines and chemokines between the 2 groups. The maximum temperature in the combo-group was lower than that in the mono-group on day 3 through day 5 (p = 0.048), particularly on day 4 (p = 0.037). Conclusion To our knowledge, this is the first prospective, randomized, clinical trial of oseltamivir and AZM combination therapy for influenza. Although the difference in inflammatory cytokine expression level was not statistically significant, combination therapy showed an early resolution of some symptoms. Name of registry University hospital Medical Information Network (UMIN). Trial Registration no UMIN000005371


Antimicrobial Agents and Chemotherapy | 2009

Efficacy of Combination Antifungal Therapy with Intraperitoneally Administered Micafungin and Aerosolized Liposomal Amphotericin B against Murine Invasive Pulmonary Aspergillosis

Takahiro Takazono; Koichi Izumikawa; Tomo Mihara; Kosuke Kosai; Tomomi Saijo; Yoshifumi Imamura; Taiga Miyazaki; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Shigeru Kohno

ABSTRACT Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and improve treatment efficacy. In the current study, we evaluated the effects of a combination treatment consisting of inhalation of aerosolized liposomal amphotericin B (L-AMB) with intraperitoneal administration of micafungin (MCFG) against murine invasive pulmonary aspergillosis. The combination of aerosolized L-AMB with intraperitoneal MCFG significantly improved the survival rate, and the fungal burdens and histopathology findings after this treatment were superior to those of the control and both monotherapy groups.


Journal of International Medical Research | 2008

Gabexate Mesilate Suppresses Influenza Pneumonia in Mice through Inhibition of Cytokines

Kosuke Kosai; Masafumi Seki; Katsunori Yanagihara; Shigeki Nakamura; Sintaro Kurihara; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Takayoshi Tashiro; Shigeru Kohno

Gabexate mesilate is a synthetic protease inhibitor that is effective for acute pancreatitis. The effect of gabexate mesilate in influenza pneumonia in mice was investigated by examining the changes in pulmonary inflammatory cytokines and chemokines. Pathological changes in the lungs of treated mice were extremely mild, compared with changes in infected, untreated mice. Intrapulmonary levels of interleukin-6 and macrophage inflammatory protein-2 decreased in treated mice compared with untreated mice, despite similar viral titres in the lungs. Survival terms for treated and untreated groups were similar. These data indicate that gabexate mesilate has beneficial effects on influenza pneumonia, which may be due to the modulation of inflammatory cytokine/chemokine responses.


Clinical and Experimental Immunology | 2008

Two-dimensional gel electrophoresis analysis in simultaneous influenza pneumonia and bacterial infection in mice.

Kosuke Kosai; Masafumi Seki; Katsunori Yanagihara; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Takayoshi Tashiro; Shigeru Kohno

Severe pneumonia is found in simultaneous influenza pneumonia and bacterial infection, and suggests a relationship with immunological mechanisms. Here, we performed two‐dimensional gel electrophoresis to detect immunological molecules related to the fulminant pneumonia caused by influenza virus and Streptococcus pneumoniae co‐infection in mice. We found two spots that were expressed strongly in co‐infected mouse lungs, compared with S. pneumoniae or influenza virus singly infected mouse lungs. The spots were analysed by mass spectrometry, and identified as alpha‐1 anti‐trypsin (A1AT), known as an anti‐protease for neutrophil‐derived proteolytic enzymes, and creatine kinase, which reflects a greater degree of lung damage and cell death. A1AT expression was increased significantly, and proteolytic enzymes from neutrophils, such as neutrophil elastase, myeloperoxidase and lysozyme, were also secreted abundantly in influenza virus and S. pneumoniae co‐infected lungs compared with S. pneumoniae or influenza virus singly infected lungs. These data suggest that A1AT may play a central role as a molecule with broad anti‐inflammatory properties, and regulation of the neutrophil‐mediated severe lung inflammation is important in the pathogenesis of co‐infection with influenza virus and bacteria.


International Journal of Oral and Maxillofacial Surgery | 2015

Efficacy of topical antibiotic administration on the inhibition of perioperative oral bacterial growth in oral cancer patients: a preliminary study

Madoka Funahara; Saki Hayashida; Yuki Sakamoto; Souichi Yanamoto; Kosuke Kosai; Katsunori Yanagihara; Masahiro Umeda

Parenteral antibiotic prophylaxis is the current standard of therapy in clean-contaminated oral cancer surgery. Nevertheless, the incidence of surgical site infection (SSI) in oral oncological surgery is relatively high, especially in major surgery with reconstruction and tracheotomy. The aims of this study were to investigate the perioperative condition related to microorganisms in the oral cavity and to examine the efficacy of the topical administration of tetracycline in reducing the number of bacteria in the oropharyngeal fluid during intubation. The number of oral bacteria was measured during intubation in patients undergoing major oral cancer surgery. The efficacy of the topical administration of tetracycline or povidone iodine gel in reducing the bacteria was then investigated. Bacteria in the oropharyngeal fluid grew from 10(6)CFU/ml to 10(8)CFU/ml during the 3h after intubation (CFU, colony-forming units). When tetracycline was applied to the dorsum of the tongue, oral bacteria decreased immediately to 10(5)CFU/ml, and the number of bacteria in the oropharyngeal fluid was maintained below 10(7)CFU/ml for 7h. The concentration of tetracycline in the oropharyngeal fluid was extremely high for several hours after topical administration. The topical administration of tetracycline could reduce oral bacteria in patients undergoing clean-contaminated oral cancer surgery. This method is expected to be effective in the prevention of SSI.

Collaboration


Dive into the Kosuke Kosai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge